FDA Approves New Antibody–Drug Conjugate for Non-Squamous Non–Small Cell Lung Cancer with c-Met Overexpression
Telisotuzumab vedotin receives accelerated approval based on LUMINOSITY trial data, demonstrating clinical benefit in previously treated patients
Med.IQ
3 min read
June 11, 2025
Sources
- Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression. Disponível em: .
Highlights
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
Written by Med.IQ
About
The first healthtech knowledge company in Latin America. We connect, create, and disseminate content with the purpose of driving change and fostering new future possibilities for doctors and patients. We enable educational solutions.